Novoron Bioscience Secures $2.5M NIH Grant to Advance Human Brain Organoid Platform for Alzheimer's Drug Discovery
核心洞察
Novoron Bioscience (搜索) received a $2.5 million SBIR grant from the National Institute on Aging to develop its human brain organoid platform for Alzheimer's drug discovery.
The platform uses human iPSC-derived cortical organoids to identify compounds that can block tau protein spread between brain cells, addressing limitations of traditional laboratory models.
The funding will support validation of a high-throughput screening system to test approximately 3,096 FDA-approved compounds for their ability to limit tau propagation.
Novoron Bioscience (搜索), a San Diego-based biotechnology company, has secured a $2.5 million Small Business Innovation Research (SBIR) grant from the National Institute on Aging at the National Institutes of Health to advance its human brain organoid platform for Alzheimer's drug discovery. The funding, awarded under Grant Number R44AG097355 in September 2025, will support the development and commercialization of a system designed to identify potential Alzheimer's drugs that can slow or stop disease progression by blocking the spread of tau between cells.
Addressing Traditional Model Limitations
The grant addresses a critical challenge in Alzheimer's research: many drug development programs fail because traditional laboratory models cannot reflect the complexity of the human brain. Novoron's platform uses human iPSC-derived cortical organoids that capture realistic cell interactions and synaptic networks, creating a more predictive setting for early drug discovery and helping narrow the field to compounds with a greater chance of clinical success.
"This award allows us to put human biology at the center of Alzheimer's drug discovery," said Travis Stiles, PhD, CEO and CSO of Novoron Bioscience (搜索). "Our organoid platform gives us a more reliable way to identify compounds that interrupt tau spread. We aim to generate clear, translatable data that supports rapid advancement into IND-enabling studies."
High-Throughput Screening Platform Development
The new funding will accelerate several planned milestones for the organoid platform. The company will validate a high-throughput organoid screening platform with functional and molecular readouts relevant to tau spread. The system supports true high-throughput screening in a 384-well format, which helps reduce early development risk by focusing attention on candidates that behave well in models with greater biological relevance than standard 2D cultures or animal studies.
A key component of the program involves running a benchmarking screen to test approximately 3,096 FDA-approved compounds for their ability to limit tau propagation. The company will then apply transcriptomic and AI-supported analyses to rank compounds based on efficacy and safety signals.
LRP1 Target and Lead Compound
A central component of the program involves LRP1 (搜索) (Low-Density Lipoprotein Receptor-Related Protein 1), which plays an important role in synaptic tau propagation. Novoron has demonstrated that its LRP1 antagonist NOVO118 can reduce tau spread. The company has also identified a druggable binding pocket within LRP1 that supports the design of selective small-molecule inhibitors, providing a strong foundation for building targeted Alzheimer's therapeutics.
Expected Outcomes and Timeline
The company expects to reach key inflection points over the course of the award, including full platform validation, identification of lead candidates, and creation of data packages suitable for investor due diligence and pharmaceutical partnering. Novoron focuses on pathways within the low-density lipoprotein receptor family, including LRP1 (搜索), with the goal of restoring function and slowing disease progression in conditions such as Alzheimer's disease, tauopathies, and spinal cord injury.